About 195 million Covid-19 vaccine doses administered in the US, according to CDC data
April 14, 2021. Summarized by summa-bot.
Compression ratio: 22.8%. 2 min read.
Nearly 195 million doses of Covid-19 vaccine have been administered in the United States, according to data published Wednesday by the US Centers for Disease Control and Prevention.
The CDC’s Advisory Committee on Immunization Practices held an emergency meeting to decide on whether to recommend extending a pause on giving the vaccine while investigators check into a possible link with rare blood clots.
The CDC’s Advisory Committee on Immunization Practices is holding an emergency meeting Wednesday to discuss cases of rare blood clots that may or may not be linked with J&J’s coronavirus vaccine.
The committee may recommend giving the vaccine only to certain age groups, since most cases appear to be among people under the age of 50, or perhaps only to men, as most cases of the rare blood clots have been among women.
Headache appears to be the main symptom among the six women who developed blood clots after receiving a Johnson & Johnson coronavirus vaccine, Dr. Tom Shimabukuro, vaccine safety lead with the US Centers for Disease Control and Prevention's Covid-19 Response Team, said during a meeting of the CDC's Advisory Committee on Immunization Practices on Wednesday.
Remember: The CDC and FDA recommend the US pause the vaccine after six reported blood clot cases among more than 6. 8 million doses of the vaccine administered in the US.
Some patients who developed blood clots after receiving a Johnson & Johnson coronavirus vaccine received the wrong treatment at first, a company representative told an emergency meeting of federal vaccine advisers Wednesday.
The Advisory Committee on Immunization Practices, which advises the US Centers for Disease Control and Prevention on vaccine issues, heard details of the six known cases of rare blood clots among about seven million people who got the vaccine in the US, plus a seventh suspected case.
The recommended pause on the use of Johnson & Johnson’s Covid-19 vaccine due to potential blood clots may be helpful in improving long-term trust in vaccine rollout, an infectious disease expert said Wednesday.
At least one vaccine trial volunteer also developed unusual blood clots after getting Johnson & Johnson’s coronavirus vaccine, a top official for the company said Wednesday.
There was one case of the concerning type of blood clot, known as cerebral venous sinus thrombosis (CVST), in September, during the Phase 3 trial of the single-dose vaccine, Maree said.
Johnson & Johnson is reviewing all reports of adverse events associated with its coronavirus vaccine to see if there are any more cases of rare blood clots that may not have been noticed, a top company official said Wednesday.
Dr. Aran Maree, chief medical officer for pharmaceuticals at J&J’s Janssen vaccine arm, detailed the known cases of blood clots for an emergency meeting of US Centers for Disease Control and Prevention vaccine advisers.